Last edition
News about
ASPA Introduces Consumer Awareness Campaigns to Combat Counterfeiting in Pharma
The Authentication Solution Providers' Association (ASPA), a proactive advocate in the fight against counterfeiting, has announced to be spearheading a robust public awareness campaign, particularly within the pharmaceutical industry.
Biotheryx Announces US FDA Clearance of Investigational New Drug Application for BTX-9341
The Company plans to initiate the Phase 1 clinical trial in the second half of 2024 and intends to enroll patients with HR+/HER2- breast cancer resistant to CDK4/6 inhibitor therapies.
Zenas BioPharma Announces Closing of Upsized USD 200 Mn Series C Preferred Stock Financing
The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital.
LSL Pharma Group Signs Binding Agreement to Acquire Target
LSL Pharma Group has entered into a binding Letter of Intent (LOI) to acquire profitable privately held, Quebec-based competing contract drug manufacturer (CDMO), Target Co.
Steriline to Showcase its Technologies in Pharma Industry in Achema 2024
Steriline, European manufacturer of standard and robotic lines for the aseptic processing of injectable drugs, has announced that it will exhibit its new technologies developed to upgrade its zero-loss philosophy.
Azurity Pharmaceuticals Receives FDA Approval for Myhibbin
Mycophenolate mofetil, an antimetabolite immunosuppressant crucial in safeguarding transplanted organs from rejection by the body's immune system, is a vital medication for organ transplant recipients.
Gossamer Bio Partners with Chiesi to Develop and Commercialize Seralutinib
Gossamer Bio, Inc. has signed a global collaboration and license deal with Chiesi Farmaceutici to develop and commercialize seralutinib.
Remidio Marks Milestone with 1000th FOP-NM Fundus Camera Placement in US
The FOP-NM, hailed as the world's first smartphone-based non-mydriatic fundus camera, has been a game-changer, eliminating the need for patient dilation and rapidly transforming retinal examinations in the US.
GIBF Announces Investment of USD 10 Million in Nectin Therapeutics
Guangzhou-Israel Biotechnology Fund (GIBF) has invested USD 10 million in Nectin Therapeutics Ltd., a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune-oncology treatments.
Solvias to Build Biologics and Cell and Gene Therapy Testing Center
Solvias has been planning to expand its global network of laboratory testing centers with a new biotech site in Research Triangle Park, N.C.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy